Drug Type Small molecule drug |
Synonyms Licarbazapine, MHD, BIA-2-005 + [4] |
Target |
Action modulators |
Mechanism SCNA modulators(Sodium voltage-gated channel alpha subunits modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H14N2O2 |
InChIKeyBMPDWHIDQYTSHX-UHFFFAOYSA-N |
CAS Registry29331-92-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09215 | Licarbazepine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mania | Phase 3 | United States | 01 Jan 2005 | |
Mania | Phase 3 | - | 01 Jan 2005 | |
Bipolar I disorder | Phase 3 | France | 01 Nov 2004 | |
Bipolar I disorder | Phase 3 | Russia | 01 Nov 2004 | |
Bipolar Disorder | Phase 3 | United States | 01 Oct 2004 | |
Bipolar Disorder | Phase 3 | Austria | 01 Oct 2004 | |
Bipolar Disorder | Phase 3 | Canada | 01 Oct 2004 | |
Bipolar Disorder | Phase 3 | Colombia | 01 Oct 2004 | |
Bipolar Disorder | Phase 3 | Czechia | 01 Oct 2004 | |
Bipolar Disorder | Phase 3 | Germany | 01 Oct 2004 |